Akari Therapeutics (AKTX) CFO Kameel Farag Buys $105K of Stock
Interim CFO Kameel Farag buys 18,830 shares of AKTX, spending over $105,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kameel Farag, Interim CFO at Akari Therapeutics, Plc ($AKTX), bought 18,830 shares at an average price of $5.58, worth about $105,005.50, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $AKTX is down 4.7% after 1 week, down 19.1% after 1 month and down 24.0% to date (from the $10.76 close on Jun 24, 2026).
AKTX
Akari Therapeutics, Plc
Key Points
- Kameel Farag, the Interim CFO of AKTX, purchased 18,830 shares on June 24, 2026, at an average price of $5.58 per share, totaling $105,005.50.
- Shares of AKTX traded at $10.76 on Friday, reflecting recent insider activity.
- HC Wainwright & Co. maintained a buy rating for AKTX with a $27.00 price target as of April 2, 2026.
Get $AKTX trade alerts by text
We text you when insiders, Congress or big funds trade $AKTX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Akari Therapeutics, Plc alert may contain errors. Disclosures
Kameel Farag, the Interim CFO of AKTX, has made a notable move by purchasing 18,830 shares of the company. This transaction took place on June 24, 2026, at an average price of $5.58 per share, amounting to a total investment of $105,005.50. This was not part of a pre-planned trading arrangement.
Insider Buying and Selling at Akari Therapeutics, Plc
On the same day, AKTX's CEO, Gaslightwala Abizer, also bought 21,063 shares. Meanwhile, James Neal made multiple purchases back in December 2025, acquiring shares at prices around $0.40. These insider activities highlight some confidence in the company's prospects.
Other Institutional Activity in AKTX
Institutional investors have shown varied interest in AKTX. Armistice Capital, LLC completely exited its position, reducing its holdings by 2,722,993 shares to zero. Similarly, Cresset Asset Management, LLC also nearly eliminated its stake, selling 821,954 shares. On a different note, IFP Advisors, Inc opened a new position with 186 shares.
Akari Therapeutics, Plc Stock Up 17.4%
Shares of AKTX traded at $10.76 on Friday. The stock's recent activity reflects insider transactions and institutional movements. Investors are keeping an eye on these changes as they assess the company's direction.
Analysts Set New Price Targets
HC Wainwright & Co. maintained its buy rating on AKTX with a price target of $27.00 as of April 2, 2026. Ladenburg Thalmann initiated coverage with a buy rating and a $1.00 target earlier this year. The consensus among analysts suggests a positive outlook for the stock.
About AKTX
AKTX is involved in developing innovative therapies and treatments, focusing on addressing unmet medical needs. The company is engaged in research and development, aiming to bring new solutions to the healthcare industry.
Bottom Line
Kameel Farag's recent share purchase in AKTX signals insider confidence in the company's future. While institutional investors have shown mixed reactions, analysts maintain a positive outlook. As always, these insights are based on past filings and do not necessarily reflect current positions.
Related Filing Alerts
Source: Kameel Farag's Form 4 filing on $AKTX (Jun 24, 2026). Find the original filing: AKTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts